GBIO Quote, Financials, Valuation and Earnings

Applied Therapeutics, Inc. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of -1899%. Generation Bio Co.'s return on equity of -84.94% beat Applied Therapeutics, Inc.'s return on equity of -77.88%.

Generation Bio Co. has a consensus price target of $6.83, signalling upside risk potential of 22.9%. On the other hand Applied Therapeutics, Inc. has an analysts' consensus of $0.25 which suggests that it could grow by 116.64%. Given that Applied Therapeutics, Inc. has higher upside potential than Generation Bio Co., analysts believe Applied Therapeutics, Inc. is more attractive than Generation Bio Co..

Generation Bio Co. has a beta of 1.959, which suggesting that the stock is 95.857% more volatile than S&P 500. In comparison Applied Therapeutics, Inc. has a beta of 1.989, suggesting its more volatile than the S&P 500 by 98.936%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio Co. pays -- of its earnings as a dividend. Applied Therapeutics, Inc. pays out -- of its earnings as a dividend.

Generation Bio Co. quarterly revenues are $1.6M, which are larger than Applied Therapeutics, Inc. quarterly revenues of $1M. Generation Bio Co.'s net income of -$5.5M is higher than Applied Therapeutics, Inc.'s net income of -$19M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while Applied Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.93x versus 16.43x for Applied Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of --. Generation Bio Co.'s return on equity of -84.94% beat CEL-SCI Corp.'s return on equity of -266.61%.

Generation Bio Co. has a consensus price target of $6.83, signalling upside risk potential of 22.9%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 808.12%. Given that CEL-SCI Corp. has higher upside potential than Generation Bio Co., analysts believe CEL-SCI Corp. is more attractive than Generation Bio Co..

Generation Bio Co. has a beta of 1.959, which suggesting that the stock is 95.857% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio Co. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Generation Bio Co. quarterly revenues are $1.6M, which are larger than CEL-SCI Corp. quarterly revenues of --. Generation Bio Co.'s net income of -$5.5M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.93x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of -19.69%. Generation Bio Co.'s return on equity of -84.94% beat Moderna, Inc.'s return on equity of -30.18%.

Generation Bio Co. has a consensus price target of $6.83, signalling upside risk potential of 22.9%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 12.21%. Given that Generation Bio Co. has higher upside potential than Moderna, Inc., analysts believe Generation Bio Co. is more attractive than Moderna, Inc..

Generation Bio Co. has a beta of 1.959, which suggesting that the stock is 95.857% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Generation Bio Co. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Generation Bio Co. quarterly revenues are $1.6M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Generation Bio Co.'s net income of -$5.5M is higher than Moderna, Inc.'s net income of -$200M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.93x versus 5.68x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -346.3% compared to Generation Bio Co.'s net margin of 52.48%. Generation Bio Co.'s return on equity of -84.94% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Generation Bio Co. has a consensus price target of $6.83, signalling upside risk potential of 22.9%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 148.17%. Given that XOMA Royalty Corp. has higher upside potential than Generation Bio Co., analysts believe XOMA Royalty Corp. is more attractive than Generation Bio Co..

Generation Bio Co. has a beta of 1.959, which suggesting that the stock is 95.857% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.

Generation Bio Co. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Generation Bio Co. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Generation Bio Co. quarterly revenues are $1.6M, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Generation Bio Co.'s net income of -$5.5M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Generation Bio Co.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Generation Bio Co. is 7.93x versus 9.04x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.